BOSTON--(뉴스와이어)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, RNA Therapies — Global Clinical Trial Landscape (2024).

This report details how RNA-based therapies have transitioned from a novel concept to an exciting frontier in modern medicine, demonstrating enormous potential for the treatment of diseases through highly-targeted mechanisms. It also provides a comprehensive overview of the current landscape, advancements, and future prospects of RNA therapeutics, focusing on their transformative impact on healthcare, and is available free of charge.

RNA therapies are at the forefront of medical advancements, poised to redefine the way we approach the treatment of some of the most challenging diseases known to humanity. RNA-based therapies offer a new frontier of therapeutic options with their versatility, effectiveness, and incredible adaptability.

The success of mRNA vaccines in the fight against COVID-19 was a clear example of how RNA therapies represented a practical option for large-scale development, as well as targeted medicine. The potential isn’t limited to vaccinations, but can also be used to combat infectious diseases, various types of cancers, and potentially offer an effective and economical way to address rare genetic disorders. The ability to target any gene in the human genome offers a breadth of potential far beyond what traditional therapies can currently achieve.

A factor that is of particular interest to medical research in RNA therapies is the unparalleled programmability. These are treatments that can be tailored with incredible precision, designed to target specific genetic markers and be modified rapidly to adapt to emerging challenges. The advancements in RNA delivery systems, such as lipid nanoparticles, are pushing the boundaries even further, ensuring that these therapies are not only effective but also safe and scalable.

The report touches on these major themes:

· Versatility of RNA Therapies:

° RNA-based therapies can target any gene, offering broad therapeutic potential beyond traditional drugs that focus solely on proteins.

° They are “programmable drugs,” allowing for rapid and flexible production, akin to gene-modified cell therapies.

· Success of mRNA Vaccines:

° The COVID-19 pandemic showcased the power of mRNA technology, leading to its rapid development and global deployment.

° The success of Pfizer and BioNTech's COVID-19 vaccine has set a precedent for further RNA-based vaccine developments targeting other infectious diseases, cancers, and metabolic disorders.

· Clinical Trials and Global Landscape:

° There has been significant growth in RNA therapy trials globally, with the Asia-Pacific region leading in trial growth rate.

° The most common areas of application include infectious diseases, oncology, and rare genetic disorders.

· Innovation in Delivery Methods:

° Advancements in delivery technologies such as lipid nanoparticles (LNPs) have enhanced the stability and effectiveness of RNA therapies, reducing potential side effects.

· Investment and Market Growth:

° There has been a substantial increase in public and private funding for RNA research, particularly in the United States and China.

° The market for RNA-based therapeutics is expected to grow significantly, driven by ongoing advancements and the successful application of these therapies in diverse areas.

· Regulatory Landscape:

° The FDA has approved over 20 RNA-based therapies, with many more in the pipeline, highlighting the evolving regulatory environment that is facilitating the rapid development of these treatments.

° Many different entities are pursuing new RNA-based technologies, which has increased significantly since the rollout of the mRNA COVID-19 vaccine.

The report highlights how the field is poised for substantial growth, driven by significant advancements in technology, increased funding, and successful clinical outcomes. RNA therapies have the potential to play a significant role in advancing patient care and invites continued interest and investment in this rapidly evolving field.

For more information and to download the full report free of charge, please visit Novotech's website or contact our media relations team.

About Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-cro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240825825969/en/